Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christine Su-Ching Ho"'
Autor:
Phey-Yen Han, Michael Limenta, Liesbet Li-Bei Tan, Christine Su-Ching Ho, Jalene Wang-Woon Poh
Publikováno v:
Proceedings of Singapore Healthcare, Vol 30 (2021)
Background: Effective benefit–risk communication to healthcare professionals plays a vital role in promoting the rational use of medicinal products. The Health Sciences Authority (HSA) of Singapore has implemented Physician Educational Materials (P
Externí odkaz:
https://doaj.org/article/bcad400710f1469ea7dafc9d76edf812
Publikováno v:
Proceedings of Singapore Healthcare, Vol 30 (2021)
Background: Effective benefit–risk communication to healthcare professionals plays a vital role in promoting the rational use of medicinal products. The Health Sciences Authority (HSA) of Singapore has implemented Physician Educational Materials (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ea79465ff06dc977e3226e035ba9b6
https://doi.org/10.1177/2010105820978992
https://doi.org/10.1177/2010105820978992
Publikováno v:
Singapore Med J
A risk management plan (RMP) contains an overview of important safety concerns associated with the use of a therapeutic product (TP) and proposed pharmacovigilance activities to monitor and manage these safety concerns in the post-approval stage. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8bd36d484477c02cd69f0b15e65936
https://doi.org/10.11622/smedj.2019111
https://doi.org/10.11622/smedj.2019111
Publikováno v:
Pharmaceutical Medicine. 32:13-20
Historically, global drug safety regulations were generally reactive and post-marketing safety monitoring comprised mainly spontaneous adverse event reporting. As a strategic move towards proactive pharmacovigilance, several drug regulatory agencies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::310fc594d16ba3b067050b3b86c54b81
https://doi.org/10.1007/s40290-017-0219-1
https://doi.org/10.1007/s40290-017-0219-1
Publikováno v:
Clinical Drug Investigation
Background and Objective As of December 2017, 20 diabetic ketosis (DK)/diabetic ketoacidosis (DKA) cases associated with sodium–glucose co-transporter 2 inhibitors (SGLT2i) had been reported to the Health Sciences Authority (HSA), Singapore. We aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f3a72d7f5ac6fe57be6603764da7bd
https://pubmed.ncbi.nlm.nih.gov/31065934
https://pubmed.ncbi.nlm.nih.gov/31065934